Inovio plans to advance synthetic hTERT cancer vaccine into clinical trials in 2014

[News]

Inovio Pharmaceuticals, Inc. announced today that in a preclinical study with two animal models, Inovio's hTERT (human telomerase reverse transcriptase) DNA cancer vaccine administered with Inovio's CELLECTRA adaptive electroporation delivery technology generated robust and broad immune responses, broke the immune system's tolerance to its self-antigens, induced T-cells with a tumor-killing function, and increased the rate of survival.

More... (http://www.news-medical.net/news/20130724/Inovio-plans-to-advance-synthetic-hTERT-cancer-vaccine-into-clinical-trials-in-2014.aspx)